Literature DB >> 28058628

A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.

Emmanuel Kontomanolis1, Achilleas Mitrakas2, Alexandra Giatromanolaki3, Dimitra Kareli2, Marianthi Panteliadou2, Stamatia Pouliliou2, Michael I Koukourakis4,5.   

Abstract

Micro-RNAs (miRNAs) have a complex role in carcinogenesis and tumour progression. Several miRNAs, such as miR-221, miR-27b and miR-132, have been implicated in the regulation of VEGF tumour angiogenic activity. In this pilot study, we assessed angiogenesis and DLL4+ vascular maturation index (VMI) in breast cancer tissues, in parallel with the plasma levels of the above-mentioned miRNAs. Significantly higher than control samples pre-operative levels were recorded in 10/11, 7/11 and 9/11 cases for the miR-221, miR-27b and miR-132, respectively. Seven days after surgery, a significant reduction of these miRNAs was noted in 6/11, 3/11 and 2/11 cases, respectively. High pre-operative levels of miR-27b were linked with node metastasis (p = 0.04). High pre-operative levels of miR-132 were linked with small tumours (p = 0.03) and her2 overexpression (p = 0.003). The DLL4+ VMI ranged from 26 to 69% (median 45%). Patients with poor DLL4+ VMI had significantly high pre-operative and post-operative levels of miR-221 (p = 0.01 and 0.02, respectively) and high post-operative levels of miR-132 (p = 0.02). It is concluded that angiogenesis-related miRs as detected in the plasma of patients may prove of a useful tool in the identification of patients with poor vascular maturation and high risk to develop metastasis. Whether such miRs may identify patients who would benefit from vascular normalization policies is a hypothesis that emerges from the current study.

Entities:  

Keywords:  Breast cancer; DLL4; miR-132; miR-221; miR-27b

Mesh:

Substances:

Year:  2017        PMID: 28058628     DOI: 10.1007/s12032-016-0881-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  34 in total

Review 1.  The Role of MicroRNAs in the Chemoresistance of Breast Cancer.

Authors:  Jing Wang; Muyi Yang; Yu Li; Bo Han
Journal:  Drug Dev Res       Date:  2015-08-27       Impact factor: 4.360

2.  Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.

Authors:  Nilay S Patel; Michael S Dobbie; Mark Rochester; Graham Steers; Richard Poulsom; Karena Le Monnier; David W Cranston; Ji-Liang Li; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

3.  miR-27b controls venous specification and tip cell fate.

Authors:  Dauren Biyashev; Dorina Veliceasa; Jacek Topczewski; Jolanta M Topczewska; Igor Mizgirev; Elena Vinokour; Alagarsamy L Reddi; Jonathan D Licht; Sergei Y Revskoy; Olga V Volpert
Journal:  Blood       Date:  2011-12-29       Impact factor: 22.113

Review 4.  Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Authors:  Felipe Ades; Dimitrios Zardavas; Ivana Bozovic-Spasojevic; Lina Pugliano; Debora Fumagalli; Evandro de Azambuja; Giuseppe Viale; Christos Sotiriou; Martine Piccart
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

5.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.

Authors:  Ji-Liang Li; Richard C A Sainson; Chern Ein Oon; Helen Turley; Russell Leek; Helen Sheldon; Esther Bridges; Wen Shi; Cameron Snell; Emma T Bowden; Herren Wu; Partha S Chowdhury; Angela J Russell; Craig P Montgomery; Richard Poulsom; Adrian L Harris
Journal:  Cancer Res       Date:  2011-07-29       Impact factor: 12.701

6.  Cancer vascularization: implications in radiotherapy?

Authors:  M I Koukourakis; A Giatromanolaki; E Sivridis; I Fezoulidis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-09-01       Impact factor: 7.038

7.  Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis.

Authors:  Emmanuel Kontomanolis; Marianthi Panteliadou; Alexandra Giatromanolaki; Stamatia Pouliliou; Eleni Efremidou; Vassilios Limberis; Georgios Galazios; Efthimios Sivridis; Michael I Koukourakis
Journal:  Med Oncol       Date:  2014-04-03       Impact factor: 3.064

Review 8.  Roles for miRNAs in endocrine resistance in breast cancer.

Authors:  Penn Muluhngwi; Carolyn M Klinge
Journal:  Endocr Relat Cancer       Date:  2015-10       Impact factor: 5.678

9.  Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.

Authors:  Isabel Stückrath; Brigitte Rack; Wolfgang Janni; Bernadette Jäger; Klaus Pantel; Heidi Schwarzenbach
Journal:  Oncotarget       Date:  2015-05-30

10.  Suppression of miR-221 inhibits glioma cells proliferation and invasion via targeting SEMA3B.

Authors:  Guilan Cai; Shanshan Qiao; Kui Chen
Journal:  Biol Res       Date:  2015-07-22       Impact factor: 5.612

View more
  2 in total

1.  Identification of miRNA biomarkers for breast cancer by combining ensemble regularized multinomial logistic regression and Cox regression.

Authors:  Juntao Li; Hongmei Zhang; Fugen Gao
Journal:  BMC Bioinformatics       Date:  2022-10-18       Impact factor: 3.307

Review 2.  Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs.

Authors:  Patrizia Leone; Alessio Buonavoglia; Rossella Fasano; Antonio Giovanni Solimando; Valli De Re; Sebastiano Cicco; Angelo Vacca; Vito Racanelli
Journal:  J Clin Med       Date:  2019-11-20       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.